This review summarizes molecular mechanisms of cardiac aging and potential pharmacological interventions for myocardial rejuvenation.
No takes yet. Share an insight, caveat, or question.
Aging population heightens CV risk; leaves open targeted myocardial therapies pending validation.
Cannatà et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: